Nov 26, 2019
NEC and VAXIMM Agree to Joint Development of Personalized Cancer Vaccine by Neoantigen
NEC and VAXIMM Agree to Joint Development of Personalized Cancer Vaccine by Neoantigen
Utilizing NEC’s state-of-the-art AI technology and VAXIMM’s original oral T-cell immunotherapy platform in joint trial agreements
NEC has decided to invest in VAXIMM
VAXIMM AG, a biotechnology company based in Switzerland and Germany, working on development of oral T-cell immunotherapy with NEC Corporation (Note 1, NEC) is based on Neoantigen. Strategic joint clinical trials and investment…
View On WordPress